Clinical Evaluation and Comparison of Two Microfluidic Antigenic Assays for Detection of SARS-CoV-2 Virus

Microorganisms, Journal Year: 2023, Volume and Issue: 11(11), P. 2709 - 2709

Published: Nov. 5, 2023

Given the ongoing pandemic, there is a need to identify SARS-CoV-2 and differentiate it from other respiratory viral infections in various critical settings. Since its introduction, rapid antigen testing spreading worldwide, but diagnostic accuracy extremely variable often disagreement with manufacturer's specifications. Our study compared clinical performances of two microfluidic tests towards molecular assay, starting positive samples. A total 151 swabs collected at Microbiology Virology Laboratory A.O. "SS Antonio e Biagio C. Arrigo" (Alessandria, Italy) for diagnosis were simultaneously tested evaluate accuracy, specificity, agreement RT-qPCR results. Both assays showed an overall 100% negative specimens, while comprised between 45.10% 54.90%. According instructions, greatest correlation antigenic was observed subset high load (18/19, 94.74%), dramatically decreased subsets. Moreover, ability Flu provides added value could be addressed epidemic context. However, in-house validation should performed due differences performance declared by manufacturers those actually obtained.

Language: Английский

Clinical Evaluating the Accuracy of the Panbio™ COVID-19/Flu A&B Rapid Panel, a Combo Antigen Rapid Diagnostic Test for the Omicron Variant and Influenza A Virus

Published: Jan. 1, 2023

It is difficult to differentiate between coronavirus disease 2019 (COVID-19) and influenza based on symptoms. In the present study, a newly developed antigen rapid diagnostic test (Ag-RDT) called PanbioTM COVID-19/Flu A&B that can simultaneously detect severe acute respiratory syndrome 2 (SARS-CoV-2) A/B virus was evaluated. Furthermore, its accuracy evaluated using 235 pairs of nasopharyngeal samples collected from patients with symptoms fever (>37.5°C). Reverse transcription polymerase chain reaction used as reference method evaluate SARS-CoV-2 detection. We confirmed Ag-RDT against Omicron variant, including BA.2 BA.5. The sensitivity 94.8% specificity 100%. addition, identify A virus, noninferiority conducted commercial Ag-RDT, which has already high in comparison viral culture (sensitivity, 94.8%; specificity, 98.4%). positive negative predictive values for were 98.5% 98.1%, respectively. A&B, clinical samples, suggests it efficacy settings.

Language: Английский

Review of HPV Testing and New Approaches in Cervical Cancer Screening

Евразийский онкологический журнал, Journal Year: 2024, Volume and Issue: 12(1), P. 85 - 98

Published: March 25, 2024

Вирус папилломы человека (ВПЧ) – самая распространенная инфекция, передающаяся половым путем, в мире. Более чем 70% случаев рака шейки матки, возникающих мире, вызывают два типа ВПЧ 16 и 18. Еще четыре онкогенных 31, 33, 45 58 реже связаны с развитием этого заболевания. В Узбекистане, как во многих других странах, существует высокая распространенность заболеваний, вызванных ВПЧ, частности рак матки. Основные стратегии профилактики включают себя вакцинацию против соблюдение безопасных сексуальных практик расширенное тестирование на ДНК ВПЧ. Отсутствие эффективных программ профилактики, а также ограниченный доступ к современным методам лечения предрака ранних стадий матки странах низким средним уровнями доходов (СНСД) приведут, по прогнозам ВОЗ, 2030 г. росту заболеваемости раком до 700 000 новых 400 смертей год. На сегодняшний день мировой практике применяются основном метода выявления ВПЧ: амплифицированные неамплифицированные. Инновационный метод vNAT (Nucleic acid testing) cо специфическими пробирками для переноса материала играют ключевую роль, упрощая диагностику повышая биобезопасность, обеспечивая быстрое точное выявление инфекции Совместные усилия масштабах мира, исследования укрепление системы здравоохранения имеют первостепенное значение преодоления влияния общественное здоровье, качестве перспективного инструмента. Human Papillomavirus (HPV) stands as the most prevalent sexually transmitted infection globally. More than of cervical cancer cases occurring worldwide are caused by two types HPV and Another four oncogenic less commonly associated with development this disease. Uzbekistan, like many nations, faces a substantial burden HPV-related diseases, notably cancer. Essential prevention strategies encompass vaccination, safe sexual practices, advanced HPV-DNA testing. The lack effective programs, well limited access to modern treatments for precancer early stages in low- middle-income countries (LMIC), will lead, according WHO forecasts, an increase incidence 700,000 new deaths per year.Today, world practice, there mainly methods used detect DNA: amplified non-amplified. innovative method specific tubes transferring material plays key role simplifying diagnosis increasing biosafety, ensuring rapid accurate detection infection.Collaborative global efforts, extensive research, healthcare capacity strengthening paramount combat HPV’s significant public health impact, offering promising tool battle.

Language: Русский